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It is now clear that angiotensin-converting enzyme (ACE) inhibitors have an important role in the management of patients after myocardial infarction. Several clinical trials have shown statistically significant reductions in mortality (SAVE, AIRE, GISSI-3, ISIS-4).1-4 Some may argue that the weight of evidence favours wide, if not universal, use of ACE inhibitors among post-infarct patients. Does this argument withstand closer scrutiny?
If not, what criteria should be used to identify which patients should be treated?
Rationale for postinfarction ACE inhibition After infarction, infarct expansion and ventricular remodelling lead to increasing ventricular volume. This has a powerful adverse effect on prognosis.5 6 There is clear evidence that ACE inhibitors reduce dilatation in patients at high risk of progressive ventricular dilatation.7-'0 Not all patients with infarction will develop ventricular dilatation. About a third do; but in a third ventricular volumes are unchanged and in the final third ventricular volumes may actually improve as the myocardium recovers from stunning." Dilatation, when it occurs, is initially adaptive and volumes stabilise in some patients, but in about 20% of those with infarcts dilatation is progressive and may ultimately lead to heart failure. ' 13 The selective strategies showed unequivocal benefit. In the AIRE study, where selection was based on clinical criteria of ventricular impairment, there were striking benefits with a reduction of 27% in mortality at a median follow up of 15 months. The investigators estimated that 15-20% of patients after myocardial infarction fulfilled study entry criteria. In the SAVE study selection was based on a radionuclide ejection fraction of <40%. Just under 40% of the population screened for the investigation fulfilled this criterion.'4 Benefit was not seen for the first nine months of follow up but by 42 months mortality was reduced by 19%. Benefit was seen regardless of Killip class at entry, suggesting that the benefits of ACE inhibition may extend beyond patients with clinical evidence of heart failure.
By contrast the benefits of a strategy of global unselected treatment are much less striking. In the one negative study of ACE inhibition after myocardial infarction (CONSENSUS II) ACE inhibitors were given very early and intravenously to unselected patients. No effect on outcome was shown. This was true across all subgroups. The initial fears that this trial engendered about the safety of early ACE inhibition were largely dispelled by the ISIS-4 and GISSI-3 studies in which oral ACE inhibitors given within 24 hours of infarction were associated with small but statistically significant reductions in mortality at 5 and 6 weeks respectively. ISIS-4 showed an overall benefit of 5 lives per 1000 patients treated. This compares with a benefit of 30 lives per 1000 patients treated at a comparable time point in the AIRE study.
Some evidence supports the hypothesis that ISIS-4 and GISSI-3 demonstrate the same effect as AIRE, namely a benefit of ACE inhibition in the 15-20% of patients with heart failure that is diluted by a neutral effect in the 80-85% of patients without heart failure. Subgroup analysis within ISIS-4 shows a trend towards greater benefit among the 13% of patients considered to be in heart failure at the time of randomisation. The GISSI-3 study offers stronger support for this view. Among patients without evidence of heart failure at entry (Killip class I), ACE inhibition reduced mortality by a mere 3 per 1000, compared with a 30 per 1000 reduction among patients with clinical evidence of failure (Killip class II and above).'5 There was, therefore, a 10-fold greater reduction in mortality among patients with heart failure on presentation.
Preliminary reports of the TRACE study offer further support for the merits of a selection policy. Patients were selected for randomisation to ACE inhibition or placebo on the basis of an echocardiographic assessment of regional wall motion abnormalities. '6 Over a median follow up of 3 years a highly significant 22% reduction in mortality was seen.
In conclusion it seems probable from the post-infarction trials that there is a heterogeneity of ACE inhibitor benefit, that benefit does not necessarily apply to all patients, and that benefits may be greatest in those patients with clinical evidence of heart failure.
How do ACE inhibitors reduce mortality? The question of how ACE inhibitors reduce mortality is central in determining an optimal strategy for patient selection. There are several possible mechanisms. Firstly, by extrapolation of the CONSENSUS'7 and SOLVD'18 data, treating those patients with heart failure may of itself lead to an improvement in prognosis. This clearly is one possible explanation for the dramatically positive results of the AIRE investigation and the suggestion in ISIS-4 and GISSI-3 that benefits may be greater in patients with heart failure.
A second possible mechanism of benefit is the limitation or prevention of adverse ventricular remodelling. Although the prevention of adverse remodelling provided the rationale for the use of ACE inhibitors after infarction, the evidence that prevention of remodelling underlies the consequent reduction in mortality is surprisingly limited. The best available evidence comes from a substudy of the SAVE investigation.'0 In this study, a strong association was seen between adverse cardiac events and ventricular dilatation. Overall, ACE inhibitors reduced both the extent of ventricular dilatation and the number of patients showing adverse events. Among those patients manifesting adverse events, ACE inhibitors failed to prevent dilatation. This finding offers some rather weak, circumstantial evidence that reduction in mortality is achieved through a reduction in the number of patients who undergo ventricular dilatation and are thereby at risk of adverse events.
The third potential benefit of ACE inhibitors after myocardial infarction is the prevention of recurrent infarction. Such a benefit might apply to all patients after infarction, irrespective of ventricular function, and might indicate a need for universal treatment. The SAVE and SOLVD studies'9 have shown that ACE inhibitors reduce the incidence of reinfarction among patients with ventricular impairment. However, in both studies the analysis leading to this conclusion has been questioned.20 21 The AIRE study did not substantiate this effect. Similarly, the ISIS-4 and
Further studies are needed to address the issue of ACE inhibition and reinfarction. Assuming that such a benefit may exist, the most important question would then become whether this benefit applied to all patientsremodellers and non-remodellers alike. If prevention of reinfarction applied only to the adverse remodelling group, the goal would remain the identification of these patients. Conversely a benefit in non-remodellers would be a strong argument for universal treatment. The reduction in reinfarction seen in the SAVE study was independent of ejection fraction at entry, suggesting that benefits might be universal. In our opinion, however, there is currently insufficient evidence to justify the rationale of treating all patients to prevent reinfarction.
It is of course possible that the reduction of mortality with ACE inhibitors is unrelated to the proposed benefits and arises in hitherto unrecognised ways. However, in the light of current knowledge, there does not seem to be a mechanistic mandate for universal treatment, and a selective approach to treatment seems the most rational strategy.
Timing of ACE inhibition
The timing of the start of ACE inhibition is central to determining strategies of selection. If, for example, ACE inhibitor benefits could be optimised by starting treatment on day 1, the need for early treatment would leave little option but to pursue a strategy of universal treatment.
Here, as elsewhere, uncertainty still prevails. On the one hand, early ACE inhibition is clearly desirable to minimise adverse remodelling.22 On the other, there continues to be concern that individual patients may be disadvantaged by starting an ACE inhibitor in the earliest phase of acute myocardial infarction. This is illustrated by the GISSI-3 study. Treatment with lisinopril was, as might be anticipated, accompanied by an increased incidence of hypotension. Though in percentage terms, mortality among those with hypotension in the control group was 36% (compared with 20% in the lisinopril group), in absolute terms there were 85 deaths in the lisinopril group compared with 60 in the control group. It therefore remains possible that the hypotension associated with early ACE inhibition may have an adverse effect on mortality. This remains a matter for speculation.
Irrespective of these concerns, the modest benefits seen in ISIS-4 and GISSI-3 suggest that there is little to be gained by very early ACE inhibition. Moreover, detailed studies of the time course of remodelling have suggested that the extent of ventricular dilatation in the first 48 hours after infarction is minimal." It seems reasonable, therefore, to delay treatment until after the first 48 hours and to start treatment as soon as possible thereafter. Few would argue that all patients with clinical evidence of heart failure early after infarction need treatment. Beyond this several strategies are possible. One possible approach is to base treatment on an estimate of left ventricular function. For example, the SAVE investigation provides a rationale for treating all patients with a radionuclide ejection fraction of <40% measured at a median of 11 days after infarction. This approach necessitates some delay in starting treatment because early assessment of ejection fraction during the first few days after infarction will be confounded by patients with stunned or hibernating myocardium whose left ventricular function may recover. Clearly, the provision of radionuclide studies in all patients early after infarction presents major logistic problems. Furthermore, there is significant variability in results between units. 23 To apply a single, universal treatment threshold based on an ejection fraction of 40% would be meaningless. It is therefore questionable whether a radionuclide ejection fraction should be used as the sole or predominant means of selection.
Echocardiography is more^readily available and cheaper than nuclear imaging. It cannot, however, be regarded as equivalent to nuclear imaging in estimating ejection fraction24 and adds further uncertainties to the use of ejection fraction as a means of patient selection. This is not to deny a role for echocardiogra- These and other methods of predicting ventricular dilatation will require further assessment. Until their value is known, we have to be pragmatic about the best means of patient selection. A reasonable approach at present seems to be to base treatment on clinical judgement. This will encompass an assessment of site of infarction, the extent of infarction assessed enzymatically and electrocardiographically, and whether reperfusion therapy has been given and whether it has been successful. A history of previous infarction should also be considered. Clearly assessment may also extend to an echocardiographic or radionuclide assessment of ventricular function and regional wall motion abnormalities.
The weakness of such an approach is its subjectivity. However, with current knowledge, over-reliance on quantitative or semiquantitative assessments to dictate treatment engenders a false sense of objectivity which may be an even greater shortcoming.
Conclusion
The statistical success seen in the ISIS-4 and GISSI-3 studies should not be used to justify a strategy of universal ACE inhibition after myocardial infarction. There is evidence that the benefits of ACE inhibition are heterogeneous and that benefits are greatest in patients with clinical evidence of heart failure. 
